BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 24518874)

  • 41. Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors.
    Govaerts SJ; Muccioli GG; Hermans E; Lambert DM
    Eur J Pharmacol; 2004 Jul; 495(1):43-53. PubMed ID: 15219819
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy.
    Trotter BW; Nanda KK; Burgey CS; Potteiger CM; Deng JZ; Green AI; Hartnett JC; Kett NR; Wu Z; Henze DA; Della Penna K; Desai R; Leitl MD; Lemaire W; White RB; Yeh S; Urban MO; Kane SA; Hartman GD; Bilodeau MT
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2354-8. PubMed ID: 21420860
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discovery of a CB
    Yang W; Gong X; Sun H; Wu C; Suo J; Ji J; Jiang X; Shen J; He Y; Aisa HA
    Eur J Med Chem; 2024 Feb; 265():116048. PubMed ID: 38150961
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
    Yan L; Huo P; Debenham JS; Madsen-Duggan CB; Lao J; Chen RZ; Xiao JC; Shen CP; Stribling DS; Shearman LP; Strack AM; Tsou N; Ball RG; Wang J; Tong X; Bateman TJ; Reddy VB; Fong TM; Hale JJ
    J Med Chem; 2010 May; 53(10):4028-37. PubMed ID: 20423086
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity.
    Manera C; Malfitano AM; Parkkari T; Lucchesi V; Carpi S; Fogli S; Bertini S; Laezza C; Ligresti A; Saccomanni G; Savinainen JR; Ciaglia E; Pisanti S; Gazzerro P; Di Marzo V; Nieri P; Macchia M; Bifulco M
    Eur J Med Chem; 2015 Jun; 97():10-8. PubMed ID: 25935384
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.
    Stern E; Muccioli GG; Bosier B; Hamtiaux L; Millet R; Poupaert JH; Hénichart JP; Depreux P; Goossens JF; Lambert DM
    J Med Chem; 2007 Nov; 50(22):5471-84. PubMed ID: 17915849
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
    Diaz P; Xu J; Astruc-Diaz F; Pan HM; Brown DL; Naguib M
    J Med Chem; 2008 Aug; 51(16):4932-47. PubMed ID: 18666769
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Medicinal Chemistry approach, pharmacology and neuroprotective benefits of CB
    Ferrisi R; Ceni C; Bertini S; Macchia M; Manera C; Gado F
    Pharmacol Res; 2021 Aug; 170():105607. PubMed ID: 34089867
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design and synthesis of fluorescent ligands for the detection of cannabinoid type 2 receptor (CB2R).
    Spinelli F; Giampietro R; Stefanachi A; Riganti C; Kopecka J; Abatematteo FS; Leonetti F; Colabufo NA; Mangiatordi GF; Nicolotti O; Perrone MG; Brea J; Loza MI; Infantino V; Abate C; Contino M
    Eur J Med Chem; 2020 Feb; 188():112037. PubMed ID: 31954990
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide.
    Murineddu G; Ruiu S; Loriga G; Manca I; Lazzari P; Reali R; Pani L; Toma L; Pinna GA
    J Med Chem; 2005 Nov; 48(23):7351-62. PubMed ID: 16279795
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor.
    Han S; Zhang FF; Qian HY; Chen LL; Pu JB; Xie X; Chen JZ
    J Med Chem; 2015 Aug; 58(15):5751-69. PubMed ID: 26151231
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo.
    Pasquini S; Botta L; Semeraro T; Mugnaini C; Ligresti A; Palazzo E; Maione S; Di Marzo V; Corelli F
    J Med Chem; 2008 Aug; 51(16):5075-84. PubMed ID: 18680276
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tricyclic pyrazoles part 7. Discovery of potent and selective dihydrothienocyclopentapyrazole derived CB2 ligands.
    Pinna G; Curzu MM; Dore A; Lazzari P; Ruiu S; Pau A; Murineddu G; Pinna GA
    Eur J Med Chem; 2014 Oct; 85():747-57. PubMed ID: 25134064
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice.
    Pasquini S; De Rosa M; Pedani V; Mugnaini C; Guida F; Luongo L; De Chiaro M; Maione S; Dragoni S; Frosini M; Ligresti A; Di Marzo V; Corelli F
    J Med Chem; 2011 Aug; 54(15):5444-53. PubMed ID: 21702498
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains.
    Janero DR; Korde A; Makriyannis A
    Methods Enzymol; 2017; 593():217-235. PubMed ID: 28750804
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
    Brogi S; Corelli F; Di Marzo V; Ligresti A; Mugnaini C; Pasquini S; Tafi A
    Eur J Med Chem; 2011 Feb; 46(2):547-55. PubMed ID: 21183257
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Probing the cannabinoid CB1/CB2 receptor subtype selectivity limits of 1,2-diarylimidazole-4-carboxamides by fine-tuning their 5-substitution pattern.
    Lange JH; van der Neut MA; Borst AJ; Yildirim M; van Stuivenberg HH; van Vliet BJ; Kruse CG
    Bioorg Med Chem Lett; 2010 May; 20(9):2770-5. PubMed ID: 20363132
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Two Affinity Sites of the Cannabinoid Subtype 2 Receptor Identified by a Novel Homogeneous Binding Assay.
    Martínez-Pinilla E; Rabal O; Reyes-Resina I; Zamarbide M; Navarro G; Sánchez-Arias JA; de Miguel I; Lanciego JL; Oyarzabal J; Franco R
    J Pharmacol Exp Ther; 2016 Sep; 358(3):580-7. PubMed ID: 27358483
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enantioselective synthesis of 1-methoxy- and 1-deoxy-2'-methyl-delta8-tetrahydrocannabinols: new selective ligands for the CB2 receptor.
    Huffman JW; Bushell SM; Joshi SN; Wiley JL; Martin BR
    Bioorg Med Chem; 2006 Jan; 14(1):247-62. PubMed ID: 16165365
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Benzofuran and pyrrole derivatives as cannabinoid receptor modulators with
    Wadea NE; Issac MM; Osman NA; Abadi AH
    Future Med Chem; 2019 Dec; 11(24):3139-3159. PubMed ID: 31838898
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.